Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)

Orgel Ryan; Wojdyla Daniel; Huberman David; Halperin Jonathan L.; Breithardt Guenter; Singer Daniel E.; Fox Keith A. A.; Hankey Graeme J.; Mahaffey Kenneth W.; Jones W. Schuyler; Patel Manesh R.

首页> 外文期刊>Circulation. Cardiovascular quality and outcomes >Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)

【24h】

Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)

机译：无间感的神经系统全身栓塞在心房颤动的患者由火箭AF（Rivaroxaban每日一次，口服，直接因子XA抑制与维生素K拮抗，用于预防心房颤动的卒中和栓塞试验）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Circulation. Cardiovascular quality and outcomes》 |2017年第5期|共3页
作者
Orgel Ryan; Wojdyla Daniel; Huberman David; Halperin Jonathan L.; Breithardt Guenter; Singer Daniel E.; Fox Keith A. A.; Hankey Graeme J.; Mahaffey Kenneth W.; Jones W. Schuyler; Patel Manesh R.;
展开▼
作者单位

Duke Univ Sch Med Duke Clin Res Inst Durham NC USA;

Duke Univ Sch Med Duke Clin Res Inst Durham NC USA;

North Carolina State Univ Dept Stat Raleigh NC USA;

Mt Sinai Med Ctr New York NY 10029 USA;

Hosp Univ Munster Dept Cardiovasc Med Munster Germany;

Massachusetts Gen Hosp Boston MA 02114 USA;

Univ Edinburgh Edinburgh Scotland;

Univ Western Australia Sch Med &

Pharmacol Crawley Australia;

Stanford Univ Sch Med Stanford CA 94305 USA;

Duke Univ Sch Med Duke Clin Res Inst Durham NC USA;

Duke Univ Sch Med Duke Clin Res Inst Durham NC USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心脏、血管（循环系）疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) [J] . Orgel Ryan, Wojdyla Daniel, Huberman David, Circulation. Cardiovascular quality and outcomes . 2017,第5期

机译：无间感的神经系统全身栓塞在心房颤动的患者由火箭AF（Rivaroxaban每日一次，口服，直接因子XA抑制与维生素K拮抗，用于预防心房颤动的卒中和栓塞试验）
2. Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts" [J] . Apostolakis Stavros, Lane Deirdre A., Banerjee Amitava Circulation: An Official Journal of the American Heart Association . 2013,第11期

机译：Acostolakis等人关于文章的信，“肾功能障碍是非衰弱性心房颤动患者中风和全身栓塞的预测因子：验证R（2）牧草（2）指数在火箭AF中的指数（Rivaroxaban曾经每日，口服，与维生素K拮抗剂相比，直接因子XA抑制预防心房颤动中的中风和栓塞试验）和阿里亚（心房颤动的抗凝和危险因素）研究队列“
3. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Analysis from the ROCKET AF trial (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) [J] . PatelM.R., HellkampA.S., LokhnyginaY., Journal of the American College of Cardiology . 2013,第6期

机译：非瓣膜性房颤患者停用利伐沙班与华法林相比的结果：ROCKET AF试验的分析（Rivaroxaban每日一次口服口服直接Xa抑制与维生素K拮抗作用相比较，以预防中风和房颤栓塞试验）
4. Incidence of Atrial Fibrillation After Percutaneous Closure of Patent Foramen Ovale and Small Atrial Septal Defects in Patients Presenting with Cryptogenic Stroke: A Case-Control Study [C] . R.F. Bonvini, R. Sztajzel, M. Righini, World Congress on Heart Disease . 2007

机译：用密码脑卒中患者经皮型卵形卵形卵形卵巢经皮和小间隔缺陷后心房颤动的发生率：案例对照研究
5. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for the prevention of stroke prophylaxis in atrial fibrillation. [D] . Harrington, Amanda. 2012

机译：阿哌沙班，达比加群，利伐沙班和华法林预防房颤预防中风的成本效益。
6. Editors Choice: Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding safety and tolerability study of four doses of AZD0837 vs. vitamin K antagonists [O] . Gregory Y.H. Lip, Lars H. Rasmussen, S. Bertil Olsson, -1

机译：编辑推荐：口服直接凝血酶抑制剂AZD0837用于预防非瓣膜性房颤患者的中风和全身性栓塞：四种剂量AZD0837和维生素K拮抗剂的随机剂量指导安全性和耐受性研究
7. Response to Letter Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS 2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts” [O] . Jonathan P. Piccini, Susanna R. Stevens, YuChiao Chang, 2013

机译：回应关于物品的信，“肾功能障碍是非衰弱性心房颤动患者中风和全身栓塞的预测因子：验证R 2 Chads 2指数在火箭AF中（rivaroxaban曾经每日，口服，直接因子XA抑制相比维生素K对患者预防心房颤动的卒中和栓塞试验的拮抗剂）和Atria（心房颤动的抗凝和危险因素）研究队列“

Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)

著录项

相似文献

相关主题

期刊订阅